Limit by status:

New methods and techniques for modifying polymer foils to improve their bio-functions using extreme ultraviolet (euv) radiation from laser plasma light sources which will be developed during the project for biomedical technology.

To develop trace element premixes which comply with food safety and environmental requirements and have a beneficial biological effect. Our task is also to measure and calculate the biologically and economically effective dose for the different animal species.

Doxebo is a liposomal formulation jointly invented by the israeli and hungarian applicants. It reduces the risk of serious, occasionally lethal adverse effect of doxil and other similar nano-drugs. In this application we propose preclinical studies necessary for regulatory approval of doxebo.

The mission of the consortium is to utilize state-of-the-art pharmaceutical approaches and develop tnf-alpha-binding protein-imprinted polymers for the specific elimination of tnf-alpha from the gastrointestinal tract hence improving the therapy of currently untreatable crohn's disease.

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.